On this page ▾
The market expects much less from Mankind Pharma than it has delivered before.
At today’s share price, buyers are assuming Mankind Pharma grows about 12% a year, forever. Over the last ten years it actually grew about 18% a year. That is a big step down from its own record. Either the market can see a problem that the published accounts do not show yet, or it is expecting a slowdown that has not happened.
- How it is valued: Discounted cash flow.
- What the price assumes: 12% growth, against 18% the model takes from its own record.
- Ten-year record: Between FY2020 and FY2026, Mankind Pharma's revenue went from ₹5,865 crore to ₹14,278 crore — it compounded at about 16% a year over 6 years.
- Biggest swing factor: India market growth. Main risk: Debt from the deal.
01Affordable medicines, everyday brands
Mankind Pharma, founded in Delhi in 1995 by R. C. Juneja and Rajeev Juneja, is one of India's largest drugmakers by domestic sales. It focuses on India rather than exports, selling prescription brands for infections, heart disease, diabetes and more, especially in smaller towns.
It also owns well-known consumer brands such as Manforce, Prega News and Gas-O-Fast. In 2024 it bought Bharat Serums and Vaccines, adding women's health and critical-care products. It listed in 2023.
02What the market is assuming
Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Mankind Pharma, next to what the model assumes from the company's own record.
The further apart these two numbers are, the bigger the bet a buyer at today's price is making.
03Mankind Pharma's record, in plain numbers
Between FY2020 and FY2026, Mankind Pharma's revenue went from ₹5,865 crore to ₹14,278 crore — it compounded at about 16% a year over 6 years. Net profit grew from ₹1,056 crore to ₹1,938 crore, about 11% a year — slower than revenue, so margins narrowed. In FY2026 it kept 13.6% of revenue as net profit — its weakest year in the period. The latest year added 17.0% to revenue, close to its own long-run pace.
Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.
Revenue and net profit by year (₹ crore)
| Year | Revenue | Net profit | Margin |
|---|---|---|---|
| FY2020 | 5,865 | 1,056 | 18.0% |
| FY2021 | 6,214 | 1,293 | 20.8% |
| FY2022 | 7,782 | 1,453 | 18.7% |
| FY2023 | 8,749 | 1,310 | 15.0% |
| FY2024 | 10,335 | 1,942 | 18.8% |
| FY2025 | 12,207 | 2,011 | 16.5% |
| FY2026 | 14,278 | 1,938 | 13.6% |
04How Mankind Pharma gets valued — and why
Discounted cash flowThis business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.
05What decides Mankind Pharma's value
India market growth
Domestic prescriptions are its core.
Chronic therapies
Moving into heart and diabetes care lifts margins.
Bharat Serums integration
The acquisition must earn back its cost.
Consumer brands
Over-the-counter products add growth.
06What could go wrong
- Debt from the deal. The Bharat Serums purchase added borrowing.
- Price controls. India's drug-price rules cap some products.
- Competition. Many companies chase the same doctors.
07What the full Mankind Pharma valuation shows
Sign in free to see the complete Mankind Pharma valuation
- ✓Fair value per share — from a ten-year discounted cash flow, every step shown
- ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch Mankind's value move
- ✓Bull, base and bear cases — and exactly which assumptions move between them
- ✓Peer comparison — against Sun Pharma, Torrent Pharma and other drugmakers
- ✓Downloadable report — the full write-up, yours to keep
08Questions people ask about Mankind Pharma
What brands does Mankind Pharma own?
Prescription brands plus consumer names such as Manforce, Prega News and Gas-O-Fast.
What is Bharat Serums and Vaccines?
A women's-health and critical-care company Mankind bought in 2024.
Does Mankind export?
Very little; it is mainly an India-focused business.
Is Mankind Pharma overvalued?
At ₹2,640 the market is pricing in roughly 12% sustained growth, against the ~18% its own record supports. That is less than it has delivered — on these numbers the market is asking the business for less than its own record, which usually means it doubts the record repeats.
What is the intrinsic value of Mankind Pharma?
It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.
How much debt does Mankind Pharma carry?
Debt to equity stands at 0.18, against 0.01 at the start of the period — the balance sheet is a core input to the cost of capital used here.